Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $20.6 million, at the high end of guidance and slightly up from Q2 2025, but down from $22 million in Q3 2024 [4][11] - Gross margin improved to 58.4%, up from 58.1% in Q3 2024 and exceeded guidance of 56-58% [4][11] - Adjusted EBITDA increased to $2 million from $1.3 million in Q3 2024, driven by reduced operating expenses [11][15] - Operating cash flow was positive at $1.1 million for Q3 2025, contributing to a year-to-date cash flow of $6.8 million compared to negative $0.3 million in the same period last year [16][17] Business Line Data and Key Metrics Changes - Preclinical sales increased sequentially and year-over-year due to growth in telemetry and respiratory product lines [12][13] - The Soho telemetry rollout expanded into additional key accounts, with increased recurring consumable demand [5] - The Biochrome amino acid analyzer for bioproduction performed well, with expectations to exceed last year's consumable revenue [5] Market Data and Key Metrics Changes - Revenue in the Americas increased sequentially by 3.6% but was down 4.4% year-over-year [12] - European revenue increased 0.3% sequentially, reflecting stronger preclinical academic shipments, but was flat year-over-year [13] - In China, revenue was down 6.3% sequentially and 19.6% year-over-year, although there is optimism regarding tariff disruptions [9][13] Company Strategy and Development Direction - The company outlined three priorities for 2025: maintain financial discipline, accelerate product adoption, and strengthen capital structure through debt refinancing [4] - The launch of the Incubate MultiWell system aims to enhance the electrophysiology portfolio and expand into high-throughput applications [6][7] - The company is actively discussing options for refinancing its credit agreement, with expectations to complete this in Q4 2025 [8][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about increased demand and backlog heading into Q4 2025, with expectations for continued momentum [9][18] - The ongoing government shutdown may impact NIH funding distribution, which is being monitored closely [8][9] - The company is fundamentally stronger than at the beginning of the year, with a leaner structure and better alignment with long-term growth opportunities [9] Other Important Information - The company expanded its distribution agreement with Fisher Scientific, enhancing access to its products across North America [7] - The adoption of the MeshMEA organoid platform is gaining momentum, supported by regulatory initiatives [8] Q&A Session Summary Question: What drove the uptick in preclinical systems during the quarter? - The uptick was driven by broad demand for telemetry products across various regions and customer groups [20] Question: Is the backlog similar to the existing product mix? - The backlog showed a uniform increase across geographies and products, not driven by any specific product [21][22] Question: What improvements are seen in the academic and government market? - Improvement is reflected in Q3 results and strong backlog, but the potential impact of NIH funding and government shutdown is considered in guidance [23] Question: How does the guidance account for NIH funding and government shutdown? - The lower range of guidance considers the potential for a prolonged government shutdown affecting funding [27] Question: Will NIH funds flow through sales in the first quarter of next year if not released in Q4? - Funds are not lost but will be delayed, potentially impacting orders in Q1 or Q2 of 2026 [28] Question: What is the status of the ERP project? - The ERP project was completed in Q4, contributing to reduced expenses and operational efficiencies [30]

All right, joining us now uh rejoining us, he hasn't left, Ken Langon, Home Depot co-founder, currently chairman and president of Invamemed Associates. The stock market will open at 9:30, but we talk about everything. So, we we will talk about the mayor and the mayor race eventually, but I want to start with this. You were talking about anti-semitism. It just made me try to figure out the the genesis of how bad it's gotten. And and I immediately thought about I don't want to blame colleges. I don't want to ...

Summary of Healthpeak Properties Conference Call Company Overview - Healthpeak Properties is a real estate investment trust (REIT) with a market capitalization of approximately $25 billion, focusing on healthcare real estate, primarily in outpatient medical facilities (60% of business), senior housing (10%), and life sciences/lab facilities (30%) [2][3] Core Business Insights - Healthpeak is the largest owner of outpatient medical facilities globally and the second or third largest owner of lab life sciences facilities [2][3] - The company has a strong tenant base, with HCA (largest for-profit health system) and CommonSpirit (largest non-profit health system) as significant tenants [4][5] - Healthpeak has demonstrated resilience during the pandemic, collecting 99% of rent and maintaining occupancy rates [7][8] Market Dynamics - The outpatient medical sector is experiencing consistent growth due to demographic trends, with 12,000 people turning 65 daily, leading to increased demand for healthcare services [12][35] - The average rent for outpatient medical space is approximately $23 per square foot, while new construction costs are significantly higher at $35 to $40 per square foot, making existing properties more attractive [13][15] - Healthpeak's outpatient medical facilities are strategically located in fast-growing markets such as Atlanta, Dallas, and Phoenix [10] Lab Space Insights - The lab real estate market has seen a temporary oversupply due to increased construction during the pandemic, leading to challenges in recruiting new tenants [22][24] - Healthpeak operates in key markets like Boston, South San Francisco, and San Diego, where demand for lab space remains strong despite current oversupply [18][22] - The company emphasizes the importance of collaboration in lab environments, providing amenities that facilitate interaction among scientists [19][20] Financial Performance and Growth - Healthpeak offers a 7% dividend based on its current stock price, with a payout ratio of 70% of cash flow [24] - The company is focused on leasing the remaining 15% of its lab space, which could generate an additional $60 to $75 million in annual rent [43] - Future growth is anticipated from the aging population and the increasing shift of healthcare services to outpatient settings [35][36] Regulatory and Funding Environment - The company is monitoring NIH funding and its impact on the lab space, noting that while direct funding remains stable, the overall capital markets have slowed down [37][40] - Healthpeak is strategically investing in "zombie buildings" through loans to capitalize on future demand once the market stabilizes [44][32] Conclusion - Healthpeak Properties is well-positioned for growth in both outpatient medical and lab spaces, leveraging demographic trends and strategic partnerships with health systems. The company remains resilient in the face of market challenges and is focused on long-term growth opportunities in the healthcare real estate sector [46][47]